Cargando…
Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
Hepatocellular carcinoma (HCC), a primary malignancy of the liver, is the second leading cause of cancer mortality worldwide. Fibroblast Growth Factor 19 (FGF19) is one of the most frequently amplified genes in HCC patients. Moreover, mice expressing an FGF19 transgene have been shown to develop HCC...
Autores principales: | Zhou, Mei, Yang, Hong, Learned, R. Marc, Tian, Hui, Ling, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5440856/ https://www.ncbi.nlm.nih.gov/pubmed/28508871 http://dx.doi.org/10.1038/ncomms15433 |
Ejemplares similares
-
Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
por: Zhou, Mei, et al.
Publicado: (2019) -
Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice
por: Zhou, Mei, et al.
Publicado: (2017) -
IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort study
por: Kao, Jung-Ta, et al.
Publicado: (2015) -
Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress
por: Yang, Chaofeng, et al.
Publicado: (2013) -
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis()()
por: Jung, In Hye, et al.
Publicado: (2015)